Maravai LifeSciences Appoints Dr. William S. Merritt as CEO
Ticker: MRVI · Form: 8-K · Filed: Jul 29, 2024 · CIK: 1823239
| Field | Detail |
|---|---|
| Company | Maravai Lifesciences Holdings, Inc. (MRVI) |
| Form Type | 8-K |
| Filed Date | Jul 29, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, board-of-directors, leadership-change
Related Tickers: MRVI
TL;DR
Maravai names Dr. Merritt permanent CEO, he's also joining the board.
AI Summary
Maravai LifeSciences Holdings, Inc. announced on July 23, 2024, the appointment of Dr. William S. Merritt as Chief Executive Officer, effective immediately. Dr. Merritt, who has been serving as interim CEO since March 2024, will also join the Board of Directors. He previously held the role of Chief Operating Officer and has been with the company since 2014.
Why It Matters
The permanent appointment of a CEO signals stability and strategic direction for Maravai LifeSciences, potentially impacting investor confidence and operational execution.
Risk Assessment
Risk Level: low — This filing reports on a routine executive appointment and board addition, with no immediate financial or operational risks indicated.
Key Players & Entities
- Maravai LifeSciences Holdings, Inc. (company) — Registrant
- Dr. William S. Merritt (person) — Appointed CEO and Board Member
- July 23, 2024 (date) — Effective date of appointment
- March 2024 (date) — Start of interim CEO role
FAQ
Who has been appointed as the new Chief Executive Officer of Maravai LifeSciences Holdings, Inc.?
Dr. William S. Merritt has been appointed as the new Chief Executive Officer.
When was the appointment of Dr. William S. Merritt as CEO effective?
The appointment was effective immediately as of July 23, 2024.
What other role will Dr. William S. Merritt assume in addition to CEO?
Dr. Merritt will also join the Board of Directors of Maravai LifeSciences Holdings, Inc.
What was Dr. Merritt's role prior to his permanent CEO appointment?
Dr. Merritt was serving as the interim CEO since March 2024 and previously held the role of Chief Operating Officer.
How long has Dr. Merritt been associated with Maravai LifeSciences?
Dr. Merritt has been with the company since 2014.
Filing Stats: 830 words · 3 min read · ~3 pages · Grade level 10.8 · Accepted 2024-07-29 16:11:14
Key Financial Figures
- $0.01 — which registered Class A Common Stock, $0.01 par value MRVI The Nasdaq Stock Market
Filing Documents
- mrvi-20240723.htm (8-K) — 33KB
- exhibit991-boardappointment.htm (EX-99.1) — 10KB
- 0001823239-24-000091.txt ( ) — 172KB
- mrvi-20240723.xsd (EX-101.SCH) — 2KB
- mrvi-20240723_lab.xml (EX-101.LAB) — 22KB
- mrvi-20240723_pre.xml (EX-101.PRE) — 13KB
- mrvi-20240723_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. A copy of the press release announcing the appointment of Mr. Martin to the Board is attached hereto as Exhibit 99.1. The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 99.1* Press Release dated July 29, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). _______________ * Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MARAVAI LIFESCIENCES HOLDINGS, INC. Date: July 29, 2024 By: /s/ Kevin M. Herde Name: Kevin M. Herde Title: Chief Financial Officer